Home » Open Orphan (ORPH) » Irish Times – Open Orphan to test Covid-19 drug through London subsidiary

Irish Times – Open Orphan to test Covid-19 drug through London subsidiary

Pharma company steps up fight against virus that has infected more than 2.6m worldwide

by Ciara O’Brien

Photograph: iStock

Dublin-listed pharma services company Open Orphan has begun testing an anti-viral treatment for Covid-19 through its London-based subsidiary Hvivo.

The testing is being carried out on behalf of Nearmedic International, a specialist pharmaceutical, biotechnological and medical company headquartered in Moscow.

The drug being tested is potentially anti-viral and anti-inflammatory, and could reduce both virus infectivity and disease severity. It will be tested against a panel of viruses including the influenza virus, circulating betacoronavirus and Covid-19.

“Hvivo is a world leading provider of services to global vaccine and antiviral development companiesand our scientists have considerable knowledge from previous anti-viral trials which gives us confidence in our testing,” said Cathal Friel, executive chairman of Open Orphan.

Open Orphan agreed to merge with UK-based Hvivo last year in a £30 million tie-up that classified as a reverse takeover. Hvivo is a clinical trial business that can accelerate drug and vaccine development.

The company previously said it would restart a project whereby humans will be deliberately infected with a coronavirus as part of efforts to develop a vaccine to Covid-19.The project was originally suspended by Hvivo after concerns there was insufficient market demand for the product.

 Read the original Irish Times article here

Leave a comment

I would like to receive Brand Communications updates and news...
Free Stock Updates & News
I agree to have my personal information transfered to MailChimp ( more information )
Join over 3.000 visitors who are receiving our newsletter and learn how to optimize your blog for search engines, find free traffic, and monetize your website.
We hate spam. Your email address will not be sold or shared with anyone else.